CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients

INTRODUCTION: Immunotherapy has limited efficacy in metastatic colorectal cancer (mCRC). Understanding mechanisms mediating immune resistance in microsatellite stable (MSS) colorectal tumors remains an ongoing challenge. Novel combination immunotherapy-based approaches have been developed under the...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Stefania, Martini, Giulia, Ciardiello, Davide, Di Maio, Massimo, Normanno, Nicola, Avallone, Antonio, Martinelli, Erika, Maiello, Evaristo, Troiani, Teresa, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272566/
https://www.ncbi.nlm.nih.gov/pubmed/35832541
http://dx.doi.org/10.3389/fonc.2022.940523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272566/
https://www.ncbi.nlm.nih.gov/pubmed/35832541
http://dx.doi.org/10.3389/fonc.2022.940523

Ejemplares similares